Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.

Schmitz, E M H

Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. [electronic resource] - Clinical rheumatology Sep 2017 - 2129-2134 p. digital

Publication Type: Journal Article; Observational Study

1434-9949

10.1007/s10067-017-3686-6 doi


Aged
Antirheumatic Agents--administration & dosage
Biosimilar Pharmaceuticals--administration & dosage
C-Reactive Protein--analysis
Drug Monitoring
Drug Substitution
Female
Humans
Infliximab--administration & dosage
Male
Middle Aged
Netherlands
Prospective Studies
Rheumatic Diseases--drug therapy
Severity of Illness Index
Treatment Outcome